ADCY1 and catecholaminergic polymorphic ventricular tachycardia: It is possible that reduction in adenylate cyclase-cAMP/PKA activity (e.g., by β-blockers) in parallel to treatment with ivabradine could provide a more effective anti-arrhythmic therapy in CPVT.